Molnupiravir

EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment.

[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.

[2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.

https://jvi.asm.org/content/92/3/e01965-17

ihttps://www.nature.com/articles/s41564-020-00835-2?fbclid=IwAR1Qo7lUr5zaPli-SVj9_B0gjDSzeu3L6QFsk-TMporW42q8NPK6MrzOoa4#author-information